Trials / Completed
CompletedNCT03374540
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
Comparative Effectiveness of Rivaroxaban and Warfarin for Stroke Prevention in Multi-morbid Patients With Nonvalvular Atrial Fibrillation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 78,517 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice. The primary objective in this study was to evaluate the combined end point of stroke or systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs. VKA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | 15/20 mg |
| DRUG | Vitamin K antagonist (VKA) | Individually adjusted dose |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
- First posted
- 2017-12-15
- Last updated
- 2020-08-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03374540. Inclusion in this directory is not an endorsement.